JP2017509585A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017509585A5 JP2017509585A5 JP2016541595A JP2016541595A JP2017509585A5 JP 2017509585 A5 JP2017509585 A5 JP 2017509585A5 JP 2016541595 A JP2016541595 A JP 2016541595A JP 2016541595 A JP2016541595 A JP 2016541595A JP 2017509585 A5 JP2017509585 A5 JP 2017509585A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- salt
- compound
- providing
- crystal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CC[C@]1[C@@](C(O*)=O)N(*)C[C@@]1Oc1nc2cc(OC)ccc2nc1C(CC=C)(F)F Chemical compound CC[C@]1[C@@](C(O*)=O)N(*)C[C@@]1Oc1nc2cc(OC)ccc2nc1C(CC=C)(F)F 0.000 description 85
- MZBLZLWXUBZHSL-FZNJKFJKSA-N CC[C@H]([C@H](C1)Oc2nc(cc(cc3)OC)c3nc2C(CCCC[C@H](C2)[C@@H]2OC(N[C@H]2C(C)(C)C)=O)(F)F)[C@@H](C(N[C@](C3)([C@@H]3C(F)F)C(NS(C3(C)CC3)(=O)=O)=O)=O)N1C2=O Chemical compound CC[C@H]([C@H](C1)Oc2nc(cc(cc3)OC)c3nc2C(CCCC[C@H](C2)[C@@H]2OC(N[C@H]2C(C)(C)C)=O)(F)F)[C@@H](C(N[C@](C3)([C@@H]3C(F)F)C(NS(C3(C)CC3)(=O)=O)=O)=O)N1C2=O MZBLZLWXUBZHSL-FZNJKFJKSA-N 0.000 description 12
- KPBVWEDYWIKGMQ-VYIYSTOKSA-N CC[C@H]([C@H](C1)Oc2nc(cc(cc3)OC)c3nc2C(CCCC[C@H](C2)[C@@H]2OC(N[C@H]2C(C)(C)C)=O)(F)F)[C@@H](C(O)=O)N1C2=O Chemical compound CC[C@H]([C@H](C1)Oc2nc(cc(cc3)OC)c3nc2C(CCCC[C@H](C2)[C@@H]2OC(N[C@H]2C(C)(C)C)=O)(F)F)[C@@H](C(O)=O)N1C2=O KPBVWEDYWIKGMQ-VYIYSTOKSA-N 0.000 description 8
- KVFIQMJEJACPPC-OPRDCNLKSA-N CC(C)(C)[C@@H](C(O)=O)NC(O[C@H]1[C@H](CC=C)C1)=O Chemical compound CC(C)(C)[C@@H](C(O)=O)NC(O[C@H]1[C@H](CC=C)C1)=O KVFIQMJEJACPPC-OPRDCNLKSA-N 0.000 description 7
- UHBJPNXGJDBGEK-SSDLBLMSSA-N CC1(CC1)S(NC([C@@](C1)([C@@H]1C(F)F)N)=O)(=O)=O Chemical compound CC1(CC1)S(NC([C@@](C1)([C@@H]1C(F)F)N)=O)(=O)=O UHBJPNXGJDBGEK-SSDLBLMSSA-N 0.000 description 6
- ZESWCZXSEHLVSF-GMTAPVOTSA-N CC(C)(C)[C@@H](C(O)=O)NC(O[C@H]1[C@H](CCC=C)C1)=O Chemical compound CC(C)(C)[C@@H](C(O)=O)NC(O[C@H]1[C@H](CCC=C)C1)=O ZESWCZXSEHLVSF-GMTAPVOTSA-N 0.000 description 5
- AMVYAAUXULQDBC-ALVVINIESA-N CC[C@H]([C@H](C1)Oc2nc3cc(OC)ccc3nc2C(CC=C)(F)F)[C@@H](C(O)=O)N1C([C@H](C(C)(C)C)NC(O[C@H]1[C@H](CC=C)C1)=O)=O Chemical compound CC[C@H]([C@H](C1)Oc2nc3cc(OC)ccc3nc2C(CC=C)(F)F)[C@@H](C(O)=O)N1C([C@H](C(C)(C)C)NC(O[C@H]1[C@H](CC=C)C1)=O)=O AMVYAAUXULQDBC-ALVVINIESA-N 0.000 description 5
- OAUBWBPEOGCJDI-LFIBNONCSA-N C=CCC(/C(/C#N)=N/c1ccccc1)(F)F Chemical compound C=CCC(/C(/C#N)=N/c1ccccc1)(F)F OAUBWBPEOGCJDI-LFIBNONCSA-N 0.000 description 2
- UEUJSSBQLVLZML-GDNBJRDFSA-N C=CCC(/C(/Cl)=N/c1ccccc1)(F)F Chemical compound C=CCC(/C(/Cl)=N/c1ccccc1)(F)F UEUJSSBQLVLZML-GDNBJRDFSA-N 0.000 description 1
- FSEADHGDCUSINU-UHFFFAOYSA-N C=CCC(C(Nc1ccccc1)=O)(F)F Chemical compound C=CCC(C(Nc1ccccc1)=O)(F)F FSEADHGDCUSINU-UHFFFAOYSA-N 0.000 description 1
- KETKBAXCCLVVML-PRHODGIISA-N C=CC[C@H](C1)[C@@H]1OC(c1cc([N+]([O-])=O)cc([N+]([O-])=O)c1)=O Chemical compound C=CC[C@H](C1)[C@@H]1OC(c1cc([N+]([O-])=O)cc([N+]([O-])=O)c1)=O KETKBAXCCLVVML-PRHODGIISA-N 0.000 description 1
- NLQZYLYKMNXZEK-HQRFULLOSA-N CC[C@H]([C@H](C1)Oc2nc(cc(cc3)OC)c3nc2C(CCCC(CC2)C[C@@H]2OC(N[C@H]2C(C)(C)C)=O)(F)F)[C@@H](C(N[C@@](C3)(C(NS(C4(C)CC4)(=O)=O)=O)C3=C(F)F)=O)N1C2=O Chemical compound CC[C@H]([C@H](C1)Oc2nc(cc(cc3)OC)c3nc2C(CCCC(CC2)C[C@@H]2OC(N[C@H]2C(C)(C)C)=O)(F)F)[C@@H](C(N[C@@](C3)(C(NS(C4(C)CC4)(=O)=O)=O)C3=C(F)F)=O)N1C2=O NLQZYLYKMNXZEK-HQRFULLOSA-N 0.000 description 1
- BGECPZBXIHJWEY-NJZATKFJSA-N CC[C@H]([C@H](C1)Oc2nc(cc(cc3)OC)c3nc2C(CCCC(CC2)C[C@@H]2OC(N[C@H]2C(C)(C)C)=O)(F)F)[C@@H](C(O)=O)N1C2=O Chemical compound CC[C@H]([C@H](C1)Oc2nc(cc(cc3)OC)c3nc2C(CCCC(CC2)C[C@@H]2OC(N[C@H]2C(C)(C)C)=O)(F)F)[C@@H](C(O)=O)N1C2=O BGECPZBXIHJWEY-NJZATKFJSA-N 0.000 description 1
- FXYRCPNERSOVPR-DOUFFDQJSA-N CC[C@H]([C@H](C1)Oc2nc(cc(cc3)OC)c3nc2C(CCCC[C@H](C2)[C@@H]2OC(N[C@H]2C(C)(C)C)=O)(F)F)[C@@H](C(N[C@@](C3)(C(NS(C4(C)CC4)(=O)=O)=O)C3=C(F)F)=O)N1C2=O Chemical compound CC[C@H]([C@H](C1)Oc2nc(cc(cc3)OC)c3nc2C(CCCC[C@H](C2)[C@@H]2OC(N[C@H]2C(C)(C)C)=O)(F)F)[C@@H](C(N[C@@](C3)(C(NS(C4(C)CC4)(=O)=O)=O)C3=C(F)F)=O)N1C2=O FXYRCPNERSOVPR-DOUFFDQJSA-N 0.000 description 1
- HMQRYTRBTAOYBM-UHFFFAOYSA-N COc1cc2nc(N)c(C(CC=C)(F)F)nc2cc1 Chemical compound COc1cc2nc(N)c(C(CC=C)(F)F)nc2cc1 HMQRYTRBTAOYBM-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361920446P | 2013-12-23 | 2013-12-23 | |
| US61/920,446 | 2013-12-23 | ||
| PCT/US2014/071319 WO2015100145A1 (en) | 2013-12-23 | 2014-12-18 | Synthesis of a macrocyclic hcv ns3 inhibiting tripeptide |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017509585A JP2017509585A (ja) | 2017-04-06 |
| JP2017509585A5 true JP2017509585A5 (enExample) | 2018-01-18 |
| JP6425727B2 JP6425727B2 (ja) | 2018-11-21 |
Family
ID=52278856
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016541595A Active JP6425727B2 (ja) | 2013-12-23 | 2014-12-18 | 大環状hcv ns3阻害トリペプチド |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US9440991B2 (enExample) |
| EP (1) | EP3087085B1 (enExample) |
| JP (1) | JP6425727B2 (enExample) |
| KR (1) | KR102366697B1 (enExample) |
| CN (3) | CN105849118B (enExample) |
| AR (1) | AR098959A1 (enExample) |
| AU (1) | AU2014370125B2 (enExample) |
| CA (1) | CA2934537C (enExample) |
| EA (1) | EA201691031A1 (enExample) |
| ES (1) | ES2724460T3 (enExample) |
| IL (1) | IL246064A0 (enExample) |
| MX (1) | MX2016008452A (enExample) |
| NZ (1) | NZ720745A (enExample) |
| PL (1) | PL3087085T3 (enExample) |
| PT (1) | PT3087085T (enExample) |
| SG (1) | SG11201604482QA (enExample) |
| SI (1) | SI3087085T1 (enExample) |
| TR (1) | TR201906413T4 (enExample) |
| TW (3) | TWI671292B (enExample) |
| WO (1) | WO2015100145A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2822285T3 (es) | 2013-07-30 | 2021-04-30 | Kronos Bio Inc | Polimorfo de inhibidores de SYK |
| MD4684B1 (ro) | 2013-07-30 | 2020-03-31 | Gilead Connecticut INc. | Formulări pe bază de imidazopirazine în calitate de inhibitori SYK |
| TR201906413T4 (tr) | 2013-12-23 | 2019-05-21 | Gilead Sciences Inc | Bir makrosiklik hcv ns3 inhibe edici tripeptidin sentezi. |
| TWI735853B (zh) | 2013-12-23 | 2021-08-11 | 美商克洛諾斯生技有限公司 | 脾酪胺酸激酶抑制劑 |
| US9809576B1 (en) | 2014-07-18 | 2017-11-07 | Abbvie Inc. | Synthetic route to anti-viral agents |
| US9809534B1 (en) * | 2014-07-21 | 2017-11-07 | Abbvie Inc. | Difluoroalkylcyclopropyl amino acids and esters, and syntheses thereof |
| US10059969B1 (en) | 2014-10-03 | 2018-08-28 | Abbvie Inc. | Process for the preparation of (S)-2-amino-non-8-enoic acid |
| US10316338B1 (en) | 2015-01-30 | 2019-06-11 | Abb Vie Inc. | Enzymatic process for the preparation of (1S,2R)-2-(difluoromethyl)-1-(propoxycarbonyl)cyclopropanecarboxylic acid |
| EP3315497B1 (en) | 2015-06-29 | 2020-01-08 | Central Glass Company, Limited | Method for producing fluorine-containing cyclopropane carboxylic acid compound |
| TWI693286B (zh) | 2017-02-01 | 2020-05-11 | 美商艾伯維有限公司 | (±)-2-(二氟甲基)-1-(烷氧羰基)-環丙烷甲酸及(±)-2-(乙烯基)-1-(烷氧羰基)-環丙烷甲酸之酶催化製法 |
| WO2019084740A1 (zh) * | 2017-10-31 | 2019-05-09 | 上海同昌生物医药科技有限公司 | 一种Glecaprevir合成中间体及其胺盐的制备方法 |
| CN107739319A (zh) * | 2017-10-31 | 2018-02-27 | 上海同昌生物医药科技有限公司 | 一种Glecaprevir合成中间体及其胺盐的制备方法 |
| CN107827748A (zh) * | 2017-11-14 | 2018-03-23 | 安徽华胜医药科技有限公司 | 一种乙酸2‑烯丙基环丙酯消旋体的合成方法 |
| KR102519417B1 (ko) | 2018-11-28 | 2023-04-10 | 삼성디스플레이 주식회사 | 스트레처블 표시 장치 |
| US11339168B2 (en) | 2019-02-22 | 2022-05-24 | Kronos Bio, Inc. | Crystalline forms of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as Syk inhibitors |
| CN116041181A (zh) * | 2023-01-04 | 2023-05-02 | 广州巨元生化有限公司 | 一种制备4-卤代-2-甲基-2-丁烯酸烃基酯的方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA200605247B (en) * | 2003-12-15 | 2007-10-31 | Japan Tobacco Inc | N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof |
| CL2008003384A1 (es) * | 2007-11-14 | 2009-12-11 | Enanta Pharm Inc | Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c. |
| WO2009134987A1 (en) | 2008-04-30 | 2009-11-05 | Enanta Pharmaceuticals, Inc. | Difluoromethyl-containing macrocyclic compounds as hepatitis c virus inhibitors |
| SI2540350T1 (sl) * | 2008-07-22 | 2015-01-30 | Merck Sharp & Dohme Corp. | Kombinacije makrocikliäśnih kinoksalinske spojine, ki je hcv ns3 proteazni inhibitor z drugimi hcv uäśinkovinami |
| US8283310B2 (en) | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2289880A1 (en) * | 2009-07-08 | 2011-03-02 | Bayer CropScience AG | 2-Pyridinylcyclopropylbenzamide fungicides |
| WO2012040040A1 (en) * | 2010-09-21 | 2012-03-29 | Merck Sharp & Dohme Corp. | Hcv ns3 protease inhibitors |
| BR112013006693B1 (pt) * | 2010-09-21 | 2022-07-12 | Enanta Pharmaceuticals, Inc | Compostos inibidores da serino protease hcv derivada de prolina macrocíclica |
| UY33775A (es) * | 2010-12-10 | 2012-07-31 | Gilead Sciences Inc | Inhibidores macrocíclicos de virus flaviviridae, composiciones farmacéuticas que los comprenden y sus usos |
| UA119315C2 (uk) * | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
| WO2015095430A1 (en) * | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Methods and intermediates for the preparation of macrolactams |
| WO2015100144A1 (en) * | 2013-12-23 | 2015-07-02 | Gilead Sciences, Inc. | Crystalline forms of a macrocyclic hcv ns3 inhibiting tripeptide |
| TR201906413T4 (tr) | 2013-12-23 | 2019-05-21 | Gilead Sciences Inc | Bir makrosiklik hcv ns3 inhibe edici tripeptidin sentezi. |
-
2014
- 2014-12-18 TR TR2019/06413T patent/TR201906413T4/tr unknown
- 2014-12-18 CN CN201480070017.2A patent/CN105849118B/zh active Active
- 2014-12-18 CN CN202310617293.7A patent/CN116813596B/zh active Active
- 2014-12-18 KR KR1020167016776A patent/KR102366697B1/ko active Active
- 2014-12-18 CN CN202010152008.5A patent/CN111320610B/zh active Active
- 2014-12-18 CA CA2934537A patent/CA2934537C/en active Active
- 2014-12-18 US US14/576,143 patent/US9440991B2/en active Active
- 2014-12-18 EA EA201691031A patent/EA201691031A1/ru unknown
- 2014-12-18 WO PCT/US2014/071319 patent/WO2015100145A1/en not_active Ceased
- 2014-12-18 JP JP2016541595A patent/JP6425727B2/ja active Active
- 2014-12-18 NZ NZ720745A patent/NZ720745A/en not_active IP Right Cessation
- 2014-12-18 PL PL14822040T patent/PL3087085T3/pl unknown
- 2014-12-18 AU AU2014370125A patent/AU2014370125B2/en active Active
- 2014-12-18 MX MX2016008452A patent/MX2016008452A/es unknown
- 2014-12-18 SG SG11201604482QA patent/SG11201604482QA/en unknown
- 2014-12-18 EP EP14822040.3A patent/EP3087085B1/en active Active
- 2014-12-18 ES ES14822040T patent/ES2724460T3/es active Active
- 2014-12-18 SI SI201431166T patent/SI3087085T1/sl unknown
- 2014-12-18 PT PT14822040T patent/PT3087085T/pt unknown
- 2014-12-22 TW TW103144804A patent/TWI671292B/zh active
- 2014-12-22 TW TW108125271A patent/TWI710547B/zh active
- 2014-12-22 TW TW109137288A patent/TWI762003B/zh active
- 2014-12-23 AR ARP140104910A patent/AR098959A1/es unknown
-
2016
- 2016-06-06 IL IL246064A patent/IL246064A0/en unknown
- 2016-08-03 US US15/227,527 patent/US10030033B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017509585A5 (enExample) | ||
| JP2016520672A5 (enExample) | ||
| ME02861B (me) | Postupak za pripremu treprostinila i njegovih derivata | |
| JP2010043124A5 (enExample) | ||
| EP3056486A3 (en) | Process for preparing intermediates for antiviral compounds | |
| JP2011126894A5 (enExample) | ||
| JP2010530373A5 (enExample) | ||
| MX2013000295A (es) | Procedimiento de preparacion de un inhibidor especifico de la trombina. | |
| GB201110520D0 (en) | Extraction of carboxylic acids with tin compounds | |
| AR098959A1 (es) | Síntesis de un compuesto antiviral e intermediarios de la misma | |
| JP2017524742A5 (enExample) | ||
| JO3263B1 (ar) | مشتق إندان سلفاميد جديد | |
| AR088296A1 (es) | Citramida de rasagilina, proceso de preparación y composicion farmaceutica | |
| RU2017145357A (ru) | Пролекарство на основе фосфамида монобензилового сложного эфира тенофовира, способ его получения и применение | |
| EP2736860A4 (en) | METHOD FOR THE PRODUCTION OF AROMATIC HYDROCARBONS FROM BYPRODUCTS OF AROMATIC CARBOXYLIC ACID AND / OR METHOD FOR THE PRODUCTION OF AN AROMATIC CARBOXYLIC ALKYL REAGER | |
| JP2014506185A5 (enExample) | ||
| EP2665705A4 (en) | PROCESS FOR THE IMPROVED PREPARATION OF SUCCINIMIDE COMPLEXES OF MOLYBDENUM OF LOW MOLECULAR WEIGHT | |
| JP2016523246A5 (enExample) | ||
| SA112330457B1 (ar) | مشتقات فينيل- ايزواوكسازول وعملية تحضيرها | |
| MX360161B (es) | Proceso para preparar compuestos antiviricos. | |
| EP2684859A4 (en) | PROCESS FOR PREPARING FLUOROUS OLEFINS WITH SUBSTITUENTS FROM ORGANIC GROUPS | |
| AR081267A1 (es) | Procedimiento de obtencion de la forma cristalina a del febuxostat | |
| JP2016517904A5 (enExample) | ||
| EA201790659A1 (ru) | Способ получения сложных эфиров карбоновых кислот в присутствии титансодержащего катализатора | |
| WO2014136047A3 (en) | A process for the preparation of 2-amino-1,3-propane diol compounds and salts thereof |